September 11, 2017, by NCI Staff
On August 30, the Food and Drug Administration (FDA) approved a type of immunotherapy called CAR T-cell therapy for certain children and young adults with a form of acute lymphoblastic leukemia (ALL). The treatment, tisagenlecleucel (Kymriah™), is the first CAR T-cell therapy to receive FDA approval.
Clara Rodríguez Fernández on 16/01/2018
CAR-T therapy has been hailed as a cure for cancer, but what really is this miraculous technology and what can we actually expect from it?